Reckitt Benckiser (RBGLY) Lifted to Buy at Societe Generale

Societe Generale upgraded shares of Reckitt Benckiser (OTCMKTS:RBGLY) from a hold rating to a buy rating in a report published on Thursday, Marketbeat.com reports.

A number of other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Reckitt Benckiser from a hold rating to a sell rating in a research note on Wednesday, March 14th. Credit Suisse Group reiterated a neutral rating on shares of Reckitt Benckiser in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. reiterated a buy rating on shares of Reckitt Benckiser in a research note on Monday, December 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $21.00.

How to Become a New Pot Stock Millionaire

Reckitt Benckiser stock opened at $16.83 on Thursday. Reckitt Benckiser has a one year low of $15.80 and a one year high of $21.79. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 1.94.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3297977/reckitt-benckiser-rbgly-lifted-to-buy-at-societe-generale.html.

Reckitt Benckiser Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl, and Strepsils brand names.

Analyst Recommendations for Reckitt Benckiser (OTCMKTS:RBGLY)

Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barrick Gold  Posts Quarterly  Earnings Results, Misses Estimates By $0.01 EPS
Barrick Gold Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Moelis & Company  Posts Quarterly  Earnings Results, Beats Expectations By $0.25 EPS
Moelis & Company Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS
Zacks: Brokerages Expect Apple  to Post $2.69 Earnings Per Share
Zacks: Brokerages Expect Apple to Post $2.69 Earnings Per Share
$0.26 EPS Expected for MoneyGram International Inc  This Quarter
$0.26 EPS Expected for MoneyGram International Inc This Quarter
Analyzing Target  & Its Competitors
Analyzing Target & Its Competitors
Critical Comparison: Ascena Retail Group  vs. Vince
Critical Comparison: Ascena Retail Group vs. Vince


© 2006-2018 Ticker Report. Google+.